In Silico Trials and the Living Heart Project

This technical report discusses the innovative approach of in silico trials in medical research, focusing on the Living Heart Project and its implications for MedTech. In silico trials utilize computational modeling and simulation to create patient-specific models, which enhance insights and methodologies while potentially replacing traditional animal and human testing. The report outlines how these trials can improve the safety and efficacy assessments of new drugs and medical devices, reduce patient numbers required for trials, and accelerate regulatory approval timelines. It highlights the recognition of in silico trials by regulatory agencies, particularly the FDA's guidance on computational modeling in medical device submissions. The report also details the role of Dassault Systèmes in pioneering in silico trials and the collaboration with Tata Consultancy Services to develop a digital heart model for athletes. Furthermore, it emphasizes the integration of advanced modeling technologies with clinical trial expertise to enhance the effectiveness of in silico trials, ultimately aiming to transform patient care and healthcare practices.